Tumor cell motility. A novel therapeutic target in bladder carcinoma, experimental and clinical results.
Surgery, chemotherapy and radiotherapy are the current modalities of tumor management. However, in systemic disease, predicted patients' cure can be achieved in but a few tumor diseases. Based on previous basic research we have highlighted that the loss of cell-cell adhesion in association with an increased tumor cell motility is an essential feature of the malignant potential of bladder tumors. Thus, we have attempted therapeutical methods differing from hitherto existing treatments by focusing on a tumor cell function we call cell motility. Characterization of so-called anti-motility drugs was performed biochemically as well analyzed by in vitro by using in established bladder carcinoma cell lines. We evaluated the potential therapeutic benefit in a model of chemically induced bladder carcinoma followed by a phase I/II trial applying anti-motility drugs in patients which were chemotherapy-resistant and having metastatic bladder cancer. Both basic research as well as the results of first translational clinical trials confirmed, that advanced bladder carcinomas can be favorably affected by inhibition of tumor cell motility.